Retatrutide may be worth waiting for if: You have not responded adequately to existing GLP-1 medications Your obesity is severe enough to benefit from the additional weight loss potential You have metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD) You are comfortable with a medication that has less real-world safety data You can wait for FDA approval without significant health deterioration Your cardiovascular status has been evaluated and heart rate increases are not contraindicated Retatrutide represents the next frontier
You cannot: Get a prescription from your doctor
After a washout period of at least 3 weeks, patients received the complementary intervention
Real-world data from over a million patients shows the opposite: GLP-1 users have 18-20% fewer blood clots than comparable patients on other diabetes medications
Instead of introducing the hormone directly, they deliver plant-based nutrients, most notably berberine and prebiotics, through your skin to help your body maintain its own hormonal balance
Regarding oral contraceptives specifically, a clinically relevant interaction with delayed gastric emptying has been documented for tirzepatide in its UK Summary of Product Characteristics (SmPC), which advises the use of a non-oral or additional contraceptive method during initiation and dose escalation